Excerpt from:
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh